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Summary:
We report the case of a 59-year-old Caucasian male with a primary 
in!ltrative BCC with vascular invasion on the right temple. An 
excision biopsy was taken and histology con!rmed BCC, 2.5mm 
thick, invading into the reticular dermis. The patient underwent a 
scar excision which demonstrated no further malignancy. The patient 
showed no clinical signs of recurrence 2 years a"er diagnosis. 
Relevance:
Basal cell carcinoma (BCC) is the most common human malignancy 
and its incidence is increasing. Less than 1% of BCCs metastasize 
and very few cases of intravascular invasion by a primary BCC have 
been reported. This report discusses the clinical features of a BCC, 
the population at risk and summarises all known cases of BCC with 
vascular invasion in the literature. 
Take Home Messages:
Due to the rarity of basal cell carcinoma with vascular invasion, there is 
a poor understanding of the disease process and the metastatic potential, 
resulting in uncertainty for clinician and patient regarding appropriate 
management.
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Introduction
Basal cell carcinoma (BCC) is the most common malignancy in 
humans and its incidence is increasing worldwide. (1) Risk factors 
include exposure to sunlight, a lower Fitzpatrick skin phototype, 
genetic factors and burn scars. (2,3) The Fitzpatrick scale is a 
classi!cation system that ranks the amount of melanin in a person’s 
skin. Both the colour of skin, and how it reacts to ultraviolet light 
are taken into consideration:
1. Skin type I never tans and always burns. Skin is pale white, eyes 
are blue or green and hair is red or blond.
2. Skin type II tans poorly and burns easily. Skin and eyes are fair.
3. Skin type III tans a"er initially burning. Skin is a darker white.
4. Skin type IV tans easily and burns minimally. Skin is light 
brown.
5. Skin type V tans darkly and rarely burns. Skin is brown.
6. Skin type VI always tans darkly and never burns. Skin is dark 
brown or black. (4)
These risk factors explain how BCCs are most frequently found on 
the head and neck of white males in their !"h to sixth decade. (2) 
Despite the high prevalence, less than 1% of cases metastasize. (2,5–
9) Of the few that do, the spread of metastases is thought to be via a 
lymphatic and haematological route. Very few cases of intravascular 
invasion by a primary BCC have been reported. (5–8,10) We 
report the rare case of a 59 year old Caucasian male with a primary 
in!ltrative BCC on his right temple with vascular invasion.
Case Report
A 59 year old gentleman was referred to Dermatology with 
a 1.5x1.5cm pearly papule on his right temple, present for 
approximately two years duration. Clinically, the lesion was thought 
to be a basal cell carcinoma. The patient has skin type 2 and 
with the exception of his father having prostate cancer, no family 
history of malignancy of any kind. Relevant past medical history 
included numerous benign skin lesions such as a trichofolliculoma 
on his right forehead. He had eczema a#ecting his face as a child, 
but not into adulthood. Social history included high sunlight 
exposure, as he has been working outside as a manual labourer for 
the past 13 years. An excision biopsy of the presenting lesion was 
taken. The histology con!rmed a basal cell carcinoma in!ltrating 
the local vasculature (!gure 1), 2.5mm thick, invading into the 
reticular dermis. CD31 immunostain (!gure 2) and BerEP4 
immunostain (!gure 3) con!rmed basal cell carcinoma within 
the vascular channels. There was positive expression of BerEP4, 
EMA, MNF116 and CK7. There was no expression of CK20 or 
TTF-1. This immunopro!le makes the lesion extremely unlikely 
to be an incidental metastatic malignancy. In addition, there was 
no clinical evidence of a second primary. The patient underwent a 
wider scar excision, which demonstrated no further malignancy. At 
follow up a"er 2 years, there was no evidence of recurrence of the 
BCC on the right temple and there was no lymphadenopathy or 
hepatosplenomegaly. The patient was subsequently discharged from 
dermatology.
Figure 1: H&E X20 magni!cation, showing basal cell carcinoma 
within vessel. 1) Island of BCC within the dermis. 2) Vascular 
space. 3) Intravascular BCC.
Figure 2: CD31 immunostain highlighting the walls of the vascular 
channels (arrowed) containing basal cell carcinoma 903x677mm 
(72 x 72 DPI). Note that the tumour does not stain with this 
antibody.
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Figure 3: BerEP4 immunostain con!rming basal cell carcinoma 
within vessels (arrowed) 677x903mm (72 x 72 DPI). The BerEP4 
antibody stains the tumour brown but does not react within the 
vessels.
Discussion
The main clinical features of a basal cell carcinoma include:
• A slow-growing, raised, solid skin lesion (plaque or nodule)
• Similar colour to normal skin, or pinkish due to increased blood 
supply
• Size varies from millimetres to centimetres in diameter
• The lesion may bleed or ulcerate (11)
As there are no clinical features that can di#erentiate a BCC 
with vascular invasion from an un-invasive lesion, biopsy and 
subsequent histology are of great importance. Until recently, 
there has been little literature on the vascular invasion of BCC. 
In 1984, Von Domarus and Stephens published a report of !ve 
metastatic BCC case studies. Two of these cases had histology 
suspicious of vascular invasion. (9) In 2012, Machan et al., 
document the !rst recorded case of primary cutaneous BCC with 
histopathologically documented venous invasion. They presented 
the case of a 51-year-old male with a lesion on his upper chest. 
Histology showed an in!ltrative and micronodular BCC, which 
widely invaded the reticular dermis. It was also identi!ed within 
a muscular venule. Intravascular tumour was con!rmed with dual 
immunohistochemistry. Further excision of the scar showed no 
further disease. (5) Three more case reports of BCC with vascular 
invasion were published in 2016: a 96-year-old female with 
intravascular BCC on the right posterior helix; (6) a 75-year-old 
male with a lesion on his le" nasal sidewall; (7) an 81-year-old 
female with an enlarging lesion on the right nasal tip. (8) The !rst 
two cases underwent Mohs micrographic surgery, the third was 
surgically excised with clinical margins of 3 mm. (6–8) Another 
case was reported in late 2018: a 61-year-old male with a lesion on 
the vertex of his scalp showed both intravascular and perineural 
invasion during Mohs micrographic surgery. Despite post-operative 
radiotherapy, the patient presented with skin gra" breakdown 4.5 
years a"er surgery and biopsy showed recurrent BCC in the bone 
marrow. (10) Excluding this last case, the longest follow up period 
reported is only four months, therefore long-term recurrences or 
metastases cannot reliably be commented on. (5–8) Table 1 provides 
a summary of all known cases of primary BCC with intravascular 
invasion.
In view of the rarity of vascular invasion of BCCs, there are no 
guidelines to dictate appropriate adjuvant treatment or prognosis. 
The British Association of Dermatologists (Britain) and the 
National Comprehensive Cancer Network (USA) recommend 
adjuvant radiotherapy for “high-risk BCCs”, but are no more 
speci!c regarding intravascular invasion. (3,12) Without available 
guidelines, the decision to treat is le" to clinical judgement and 
the local multi-disciplinary team. Although the cases summarised 
appear to have minimal vascular invasion and no cases of 
metastases since 1984, the rarity of this condition results in a poor 
understanding of the disease process, its potential to metastasize and 
therefore the appropriate treatment plan.
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